PRICES include / exclude VAT
Homepage>BS Standards>07 MATHEMATICS. NATURAL SCIENCES>07.120 Nanotechnologies>PD ISO/TR 17302:2015 Nanotechnologies. Framework for identifying vocabulary development for nanotechnology applications in human healthcare
Sponsored link
immediate downloadReleased: 2015-12-31
PD ISO/TR 17302:2015 Nanotechnologies. Framework for identifying vocabulary development for nanotechnology applications in human healthcare

PD ISO/TR 17302:2015

Nanotechnologies. Framework for identifying vocabulary development for nanotechnology applications in human healthcare

Format
Availability
Price and currency
English Secure PDF
Immediate download
266.20 EUR
You can read the standard for 1 hour. More information in the category: E-reading
Reading the standard
for 1 hour
26.62 EUR
You can read the standard for 24 hours. More information in the category: E-reading
Reading the standard
for 24 hours
79.86 EUR
English Hardcopy
In stock
266.20 EUR
Standard number:PD ISO/TR 17302:2015
Pages:30
Released:2015-12-31
ISBN:978 0 580 76119 5
Status:Standard
DESCRIPTION

PD ISO/TR 17302:2015


This standard PD ISO/TR 17302:2015 Nanotechnologies. Framework for identifying vocabulary development for nanotechnology applications in human healthcare is classified in these ICS categories:
  • 07.120 Nanotechnologies

This Technical Report will not attempt a formal, comprehensive definition of “nanomedicine”. Instead, it will provide a taxonomic framework for the development of vocabulary for clinical applications of nanotechnologies in human healthcare. While it is understood that the origins of nanotechnologies for healthcare applications emerge from pre-clinical and translational research, the interest of this Technical Report is to determine where these technologies will impact the clinical value chain and the practice of medicine.

This Technical Report is intended to facilitate communications between developers and users of nanotechnologies, deliverers and users of medicine including the pharmaceutical, research and medical communities, regulatory professionals, and additional organizations and individuals who might interact with these groups, including biotechnology, diagnostic, and medical device companies, the life sciences, patent attorneys and patent offices, institutional review boards, ethics review boards, and accreditation organizations.